<DOC>
	<DOCNO>NCT00835796</DOCNO>
	<brief_summary>The objective study compare relative bioavailability finasteride 5 mg tablet ( manufacture distribute TEVA Pharmaceuticals USA ) PROSCARÂ® 5 mg tablet ( Merck ) healthy , adult , non-smoking , male subject non-fasting condition .</brief_summary>
	<brief_title>Finasteride 5 mg Tablets , Non-fasting</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Finasteride</mesh_term>
	<criteria>All subject select study male nonsmoker least 18 year age . Subjects BMI ( body mass index ) 30 less . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow : Hematology : hemoglobin , hematocrit , red blood cell count , platelet count , white blood cell count ( differential ) . Clinical Chemistry : creatinine , BUN , glucose , SGOT/AST , SGPT/ALT , bilirubin , alkaline phosphatase . Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell . HIV Screen : prestudy Hepatitis B , C Screen : prestudy Drugs Abuse Screen : prestudy checkin Subjects select normal . Electrocardiograms participate subject record initiation study file subject 's case report form . Subjects history chronic alcohol consumption ( past 2 year ) , drug addiction , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range retesting , subject significant . Subjects history allergic response class drug test exclude study . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure study period checkin . subject find urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . Subjects tolerate venipuncture allow participate . Subjects use tobacco form eligible participate study . Three month abstinence require . Females eligible participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>